GC 021109

Drug Profile

GC 021109

Alternative Names: GC-021109

Latest Information Update: 23 Dec 2015

Price : $50

At a glance

  • Originator Tufts University
  • Developer GliaCure
  • Class Anti-inflammatories; Antidementias; Small molecules
  • Mechanism of Action Glial cell modulators; Purinoceptor P2Y6 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 14 Dec 2015 GliaCure plans a phase II trial for Alzheimer's disease in USA
  • 14 Dec 2015 GliaCure completes a phase I trial for Alzhemer's disease in USA (NCT02386306)
  • 01 Feb 2015 Phase-I clinical trials in Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top